X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2578) 2578
science & technology (2524) 2524
life sciences & biomedicine (2464) 2464
everolimus (2277) 2277
female (1620) 1620
sirolimus - analogs & derivatives (1613) 1613
male (1524) 1524
middle aged (1274) 1274
sirolimus - administration & dosage (1085) 1085
aged (1079) 1079
treatment outcome (1046) 1046
oncology (824) 824
cardiovascular system & cardiology (739) 739
cardiac & cardiovascular systems (720) 720
everolimus - administration & dosage (706) 706
drug-eluting stents (678) 678
adult (644) 644
sirolimus - therapeutic use (544) 544
time factors (507) 507
immunosuppressive agents - administration & dosage (478) 478
tor serine-threonine kinases - antagonists & inhibitors (432) 432
animals (429) 429
transplantation (421) 421
care and treatment (408) 408
immunosuppressive agents - therapeutic use (385) 385
prosthesis design (385) 385
cardiovascular agents - administration & dosage (370) 370
prospective studies (362) 362
surgery (355) 355
sirolimus - adverse effects (354) 354
risk factors (335) 335
coronary artery disease - therapy (333) 333
cancer (327) 327
antineoplastic combined chemotherapy protocols - therapeutic use (325) 325
analysis (322) 322
antineoplastic agents - therapeutic use (315) 315
angiogenesis inhibitors (312) 312
stent (308) 308
pharmacology & pharmacy (302) 302
follow-up studies (284) 284
stents (278) 278
kidney neoplasms - drug therapy (276) 276
coronary angiography (274) 274
carcinoma, renal cell - drug therapy (272) 272
everolimus - adverse effects (272) 272
everolimus - therapeutic use (270) 270
medicine & public health (261) 261
sirolimus - pharmacology (260) 260
immunosuppressive agents - adverse effects (256) 256
abridged index medicus (250) 250
absorbable implants (241) 241
metastasis (239) 239
research (234) 234
percutaneous coronary intervention - instrumentation (232) 232
retrospective studies (228) 228
aged, 80 and over (226) 226
drug therapy, combination (218) 218
drug therapy (217) 217
clinical trials (215) 215
percutaneous coronary intervention - adverse effects (215) 215
percutaneous coronary intervention (212) 212
mtor (209) 209
disease-free survival (207) 207
cardiovascular (198) 198
antineoplastic agents - administration & dosage (196) 196
kaplan-meier estimate (195) 195
health aspects (193) 193
patients (193) 193
dose-response relationship, drug (192) 192
breast cancer (191) 191
rapamycin (191) 191
kidney transplantation (178) 178
tumors (176) 176
breast neoplasms - drug therapy (175) 175
mice (172) 172
tor serine-threonine kinases - metabolism (170) 170
kidney neoplasms - pathology (163) 163
antineoplastic agents - adverse effects (162) 162
cell line, tumor (160) 160
graft rejection - prevention & control (158) 158
angioplasty, balloon, coronary - instrumentation (155) 155
coronary artery disease - diagnostic imaging (155) 155
paclitaxel - administration & dosage (153) 153
kidneys (149) 149
sirolimus (149) 149
chemotherapy (148) 148
drug administration schedule (147) 147
thrombosis (145) 145
randomized controlled trials as topic (143) 143
drug-eluting stent (142) 142
protein kinase inhibitors - therapeutic use (141) 141
immunosuppressive agents - pharmacology (138) 138
antineoplastic combined chemotherapy protocols - adverse effects (137) 137
immunology (137) 137
young adult (137) 137
urology & nephrology (136) 136
carcinoma, renal cell (133) 133
cardiology (133) 133
everolimus - pharmacology (133) 133
kinases (133) 133
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3014) 3014
Japanese (33) 33
French (15) 15
German (13) 13
Russian (7) 7
Spanish (7) 7
Italian (4) 4
Norwegian (3) 3
Hungarian (2) 2
Polish (2) 2
Czech (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides | Index Medicus
Journal Article
Journal Article
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 07/2018, Volume 84, Issue 7, pp. 1575 - 1586
AIMS: Everolimus is a drug from the class of mammalian target of rapamycin inhibitors used for both immunosuppressant and oncological indications. We postulate... 
transplant | everolimus | cancer | nonmem | dose individualization | population pharmacokinetics | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Immunosuppressive Agents - pharmacokinetics | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Biological Availability | Male | Metabolic Clearance Rate | Everolimus - administration & dosage | Prednisolone - pharmacokinetics | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Drug Therapy, Combination - adverse effects | Everolimus - pharmacokinetics | Everolimus - adverse effects | Adult | Female | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Transplantation, Homologous - adverse effects | Drug Administration Schedule | Administration, Oral | Graft Rejection - prevention & control | Treatment Outcome | Tacrolimus - pharmacokinetics | Tacrolimus - adverse effects | Neoplasms - drug therapy | TOR Serine-Threonine Kinases - immunology | Drug Therapy, Combination - methods | Models, Biological | Neoplasms - immunology | Immunosuppressive Agents - adverse effects | Aged | Graft Rejection - immunology | Kidney Transplantation - adverse effects | Dosage and administration | Corticosteroids | Analysis | Prednisolone | Index Medicus | Original
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 5, pp. 876 - 884
Abstract Background LY2584702 tosylate (hereafter referred to as LY2584702) is an oral, selective ATP competitive inhibitor of p70 S6 kinase. Preclinical... 
Hematology, Oncology and Palliative Medicine | p70 S6 kinase inhibitor | LY2584702 tosylate | Erlotinib | Everolimus | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Neoplasms - metabolism | Area Under Curve | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Metabolic Clearance Rate | Fatigue - chemically induced | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Time Factors | Adult | Female | Quinazolines - administration & dosage | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacokinetics | Sirolimus - adverse effects | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Sirolimus - analogs & derivatives | Drug Administration Schedule | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Pyrimidines - administration & dosage | Ribosomal Protein S6 Kinases, 70-kDa - antagonists & inhibitors | Treatment Outcome | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Vomiting - chemically induced | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Quinazolines - adverse effects | Pyrimidines - pharmacokinetics | Anorexia - chemically induced | Aged | Adaptor Proteins, Signal Transducing - metabolism | Neoplasms - pathology | Clinical trials | Care and treatment | Product development | Tumors | Index Medicus | Life Sciences | Cancer
Journal Article
Journal Article